A Phase II Trial of PLX3397 in the Treatment of KIT Mutated Advanced Acral and Mucosal Melanoma
Phase of Trial: Phase II
Latest Information Update: 28 Jul 2016
At a glance
- Drugs Pexidartinib (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- Acronyms PIANO
- 07 Jun 2017 Biomarkers information updated
- 13 Dec 2015 Accrual till date is 4% according to United Kingdom Clinical Research Network record.
- 09 Dec 2015 Planned End Date changed from 1 May 2019 to 1 Oct 2019 as reported by ClinicalTrials.gov record.